Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31078368 | 0.99 | HDAC1 (0.51) | HDAC1HDAC6HTR2AHTR2CKDM4E | |
| Hydrochloric Acid SCHEMBL2241958 | 0.99 | HDAC1 (0.51) | HDAC1HDAC6HTR2AHTR2CKDM4E | |
| Hydrochloric Acid SCHEMBL31078359 | 0.93 | HDAC1 (0.49) | HDAC1HDAC6HTR2AHTR2CKDM4E | |
| Hydrochloric Acid SCHEMBL31078231 | 0.90 | HDAC1 (0.47) | HDAC1HDAC6HTR2AHTR2CKDM4E | |
| Hydrochloric Acid SCHEMBL31078547 | 0.85 | HDAC1 (0.45) | HDAC1HDAC6HTR2AHTR2CKDM4E | |
| SCHEMBL2357949 | 0.81 | HDAC1 (0.55) | HDAC1HDAC6HTR2AHTR2CKDM4E | |
| SCHEMBL30873508 | 0.81 | HDAC1 (0.55) | HDAC1HDAC6HTR2AHTR2CKDM4E | |
| SCHEMBL2192008 | 0.79 | HDAC1 (0.56) | HDAC1HDAC6HTR2AHTR2CKDM4E | |
| SCHEMBL8025072 | 0.79 | HDAC1 (0.69) | HDAC1HDAC6CA1CA2HTR6 | |
| SCHEMBL2187576 | 0.78 | HDAC1 (0.55) | HDAC1HDAC6HTR2AHTR2CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170879-B1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2013-01-16 | — | — | EP | disclosed |
| US-8008279-B2 | Compound—827 | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| US-8008279-B2 | Compound—827 | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| WO-2009001129-A9 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | WO | disclosed |
| US-20090012077-A1 | Novel Compound - 827 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012077-A1 | Novel Compound - 827 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| WO-2009001129-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012077-A1 | Novel Compound - 827 | CTSS, CTSF, CTSB | HDAC1 340/4885HDAC6 121/4885HTR2A 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.